2026-525790-39-00RecruitingPhase 1
A study to investigate the repeat-dose pharmacokinetics of a combined oral contraceptive when given alone and in combination with ganfeborole in female participants of non-childbearing potential.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 7 Oct 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (estimated)
- First submitted
- 31 Mar 2026
- Start date
- 20 Aug 2026
- Lead sponsor
- Glaxosmithkline Research & Development Limited
- Diseases
- Tuberculosis
- EU CT number
- 2026-525790-39-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 28
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adult women who cannot become pregnant. It studies how a birth control pill behaves in the body alone and together with ganfeborole.
- Age
- 18 years or older
- Sex
- Women only
Read by machine on 9 Nov 2026.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Universitario La Paz | Madrid | Spain | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.